Matches in Wikidata for { <http://www.wikidata.org/entity/Q37550018> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- Q37550018 description "article científic" @default.
- Q37550018 description "article scientifique" @default.
- Q37550018 description "articolo scientifico" @default.
- Q37550018 description "artigo científico" @default.
- Q37550018 description "artículu científicu espublizáu en 2014" @default.
- Q37550018 description "bilimsel makale" @default.
- Q37550018 description "scientific article published on 30 January 2014" @default.
- Q37550018 description "vedecký článok" @default.
- Q37550018 description "vetenskaplig artikel" @default.
- Q37550018 description "videnskabelig artikel" @default.
- Q37550018 description "vědecký článek" @default.
- Q37550018 description "wetenschappelijk artikel" @default.
- Q37550018 description "wissenschaftlicher Artikel" @default.
- Q37550018 description "наукова стаття, опублікована в січні 2014" @default.
- Q37550018 description "научни чланак" @default.
- Q37550018 description "գիտական հոդված հրատարակված 2014 թվականի հունվարի 30-ին" @default.
- Q37550018 description "مقالة علمية نشرت في 30 يناير 2014" @default.
- Q37550018 name "Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy." @default.
- Q37550018 name "Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy." @default.
- Q37550018 name "Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy." @default.
- Q37550018 type Item @default.
- Q37550018 label "Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy." @default.
- Q37550018 label "Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy." @default.
- Q37550018 label "Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy." @default.
- Q37550018 prefLabel "Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy." @default.
- Q37550018 prefLabel "Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy." @default.
- Q37550018 prefLabel "Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy." @default.
- Q37550018 P1433 Q37550018-C4F74A3F-9DD5-4C1E-B7D4-42BB98EB6092 @default.
- Q37550018 P1476 Q37550018-93407320-02A7-45C3-8E6B-7A389F6C8C7E @default.
- Q37550018 P2093 Q37550018-3DB5F777-7EFE-4BF1-AAE7-34B8C9C2843E @default.
- Q37550018 P2093 Q37550018-4E28383E-FB0E-4FCA-888B-5DFB02962555 @default.
- Q37550018 P2860 Q37550018-139A07EF-1296-4A26-9D35-7E95FAE5A368 @default.
- Q37550018 P2860 Q37550018-1407E512-C3D2-45D6-985A-E32996A24248 @default.
- Q37550018 P2860 Q37550018-41C2DD61-9B49-4F98-981A-8857AD827CEC @default.
- Q37550018 P2860 Q37550018-51092DB0-ADD6-4EC9-8FD8-8B83D2A1D6A5 @default.
- Q37550018 P2860 Q37550018-512158E9-6F15-485A-B034-1DB996205E95 @default.
- Q37550018 P2860 Q37550018-5E6AABA3-782A-4876-9020-302EEC4AA820 @default.
- Q37550018 P2860 Q37550018-6E5FCE18-9E7A-422B-B256-BE882B25CBE3 @default.
- Q37550018 P2860 Q37550018-938BA32A-F6E2-4E8B-914E-2D3139C87460 @default.
- Q37550018 P2860 Q37550018-9E83CB30-A709-4D73-875F-EC8553AC8160 @default.
- Q37550018 P2860 Q37550018-A45FCA42-3747-4A92-9617-9AC175BFA026 @default.
- Q37550018 P2860 Q37550018-A80CC3E7-065D-4875-BA1C-A871BC7A0510 @default.
- Q37550018 P2860 Q37550018-B52C0A58-0400-4EC4-B5D5-8D525BD66B03 @default.
- Q37550018 P2860 Q37550018-BC15608F-F309-41B6-B3E4-A473E303EB39 @default.
- Q37550018 P2860 Q37550018-D38510C6-1AD2-4627-850B-F1A2453509C3 @default.
- Q37550018 P2860 Q37550018-E6AB60F5-D96A-40C6-A4A0-A029446CA1FB @default.
- Q37550018 P31 Q37550018-0DF23F60-3735-4760-BDAB-14FE8ACE900F @default.
- Q37550018 P31 Q37550018-2fcc1e37-4f06-49d4-806c-65ca6d52ce52 @default.
- Q37550018 P356 Q37550018-D8C8CC48-F176-4F8F-B26D-F9EB53B3AABB @default.
- Q37550018 P478 Q37550018-0F386DF3-08B6-4331-A832-63FFB789F233 @default.
- Q37550018 P50 Q37550018-3161DCF9-221B-4337-9FDC-56DDDE824197 @default.
- Q37550018 P577 Q37550018-7EE00E49-3AD7-42B4-A670-6FB30D5F0C0D @default.
- Q37550018 P5875 Q37550018-83225834-1817-4E24-A3AD-6281EBEF3EE2 @default.
- Q37550018 P698 Q37550018-F6F672A9-AC46-40C7-82CF-7F8CF671F1A2 @default.
- Q37550018 P932 Q37550018-DA3AABFF-8132-4054-B794-A061C4371F5B @default.
- Q37550018 P356 BCR-2013-202861 @default.
- Q37550018 P698 24481018 @default.
- Q37550018 P1433 Q27723081 @default.
- Q37550018 P1476 "Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy" @default.
- Q37550018 P2093 "Jason Adhikaree" @default.
- Q37550018 P2093 "Yvette Newby" @default.
- Q37550018 P2860 Q24633284 @default.
- Q37550018 P2860 Q28254528 @default.
- Q37550018 P2860 Q28275006 @default.
- Q37550018 P2860 Q32034470 @default.
- Q37550018 P2860 Q34570396 @default.
- Q37550018 P2860 Q37180860 @default.
- Q37550018 P2860 Q37297529 @default.
- Q37550018 P2860 Q37615175 @default.
- Q37550018 P2860 Q38134493 @default.
- Q37550018 P2860 Q40038407 @default.
- Q37550018 P2860 Q41904942 @default.
- Q37550018 P2860 Q42829926 @default.
- Q37550018 P2860 Q51054343 @default.
- Q37550018 P2860 Q84404273 @default.
- Q37550018 P2860 Q84938013 @default.
- Q37550018 P31 Q13442814 @default.
- Q37550018 P31 Q2782326 @default.
- Q37550018 P356 "10.1136/BCR-2013-202861" @default.
- Q37550018 P478 "2014" @default.
- Q37550018 P50 Q57617617 @default.
- Q37550018 P577 "2014-01-30T00:00:00Z" @default.
- Q37550018 P5875 "259988548" @default.
- Q37550018 P698 "24481018" @default.
- Q37550018 P932 "3912364" @default.